{"nctId":"NCT01766076","briefTitle":"Atorvastatin for HAART Suboptimal Responders","startDateStruct":{"date":"2013-01"},"conditions":["Acquired Immune Deficiency Syndrome Virus"],"count":30,"armGroups":[{"label":"atorvastatin, Lipitor®","type":"EXPERIMENTAL","interventionNames":["Other: atorvastatin, Lipitor®","Drug: Placebo"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: atorvastatin, Lipitor®","Drug: Placebo"]}],"interventions":[{"name":"atorvastatin, Lipitor®","otherNames":["Lipitor®"]},{"name":"Placebo","otherNames":["atorvastatin placebo"]}],"eligibilityModule":{"eligibilityCriteria":"List of inclusion Criteria: HIV-infected adults on antiretroviral therapy for at least 6 years with sustained viral suppression (viral load\\<400 copies), and CD4 increase below 300 cells (difference between current and baseline CD4 count).\n\nList of exclusion Criteria: History of an opportunistic infection within the previous six months, Pregnancy, History of myositis, History of ingestion of lipid-lowering agents at the baseline visit, Use of therapeutic agents known to have substantial drug-drug interactions with statins, and individuals on PI-containing HAART","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"90 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage Change in Immune Activation Levels After 12 Weeks of Atorvastatin 80mg Daily","description":"Immune activation was measured by co-expression of CD38 and HLADR on CD4 T-cells (CD4+CD38+HLADR+) Mean percentage change at 12 weeks was calculated","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":15},"commonTop":["Myalgia","Chest pain","headache","Joint pains","backache"]}}}